Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck

Head and Neck

Volumn 36, Issue 4, 2014, Pages 474-480

  Hutcheson, Katherine A ^a   Lewin, Jan S ^a   Holsinger, F Christopher ^a   Steinhaus, Ganene ^a   Lisec, Asher ^a   Barringer, Denise A ^a   Lin, Heather Y ^a   Villalobos, Sandra ^a   Garden, Adam S ^a   Papadimitrakopoulou, Vali ^a   Kies, Merrill S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

functional outcomes; induction chemotherapy; locally advanced squamous carcinoma; sequential chemoradiotherapy; swallowing

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DYSPHAGIA; ESOPHAGUS STENOSIS; ESOPHAGUS SURGERY; FEEDING APPARATUS; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GASTROSTOMY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERBARIC OXYGEN; HYPOPHARYNX CANCER; INDUCTION CHEMOTHERAPY; LARYNGECTOMY; LARYNX CANCER; LARYNX CARCINOMA; LOCAL THERAPY; LONG TERM SURVIVAL; MALE; MANDIBLE RESECTION; MD ANDERSON DYSPHAGIA INVENTORY; MIDDLE AGED; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CANCER; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION INJURY; RECURRENT ASPIRATION; SPINDLE CELL SARCOMA; STRIDOR; SWALLOWING; TRACHEOSTOMY;

FUNCTIONAL OUTCOMES; INDUCTION CHEMOTHERAPY; LOCALLY ADVANCED SQUAMOUS CARCINOMA; SEQUENTIAL CHEMORADIOTHERAPY; SWALLOWING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DEGLUTITION DISORDERS; FEMALE; GASTROSTOMY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY, ADJUVANT;

EID: 84896117826     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23330     Document Type: Article

References (28)

1. Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009; 31: 748-758.
2. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
3. Rosenthal DI, Lewin JS, Eisbruch A,. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24: 2636-2643.
4. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 23-28.
5. Caudell JJ, Schaner PE, Meredith RF, et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 73: 410-415.
6. Francis DO, Weymuller EA Jr, Parvathaneni U, Merati AL, Yueh B,. Dysphagia, stricture, and pneumonia in head and neck cancer patients: does treatment modality matter? Ann Otol Rhinol Laryngol 2010; 119: 391-397.
7. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101: 142-152.
8. Garden AS, Harris J, Trotti A, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008; 71: 1351-1355.
9. Givens DJ, Karnell LH, Gupta AK, et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1209-1217.
10. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15: 1179-1186.
11. Barringer DA, Hutcheson KA, Sturgis EM, Kies MS, Lewin JS,. Effect of induction chemotherapy on speech and swallowing function in patients with oral tongue cancer. Head Neck 2009; 31: 611-617.
12. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14.
13. Logemann J,. A manual for videofluoroscopic swallow studies. 2nd ed. Austin, TX: Pro-Ed; 1993.
14. Rademaker AW, Pauloski BR, Logemann JA, Shanahan TK,. Oropharyngeal swallow efficiency as a representative measure of swallowing function. J Speech Hear Res 1994; 37: 314-325.
15. Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL,. A penetration-aspiration scale. Dysphagia 1996; 11: 93-98.
16. Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001; 127: 870-876.
17. List MA, Ritter-Sterr C, Lansky SB,. A performance status scale for head and neck cancer patients. Cancer 1990; 66: 564-569.
18. Tsai CJ, Hofstede TM, Sturgis EM, et al. Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2013; 85: 415-420.
19. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.
20. Logemann JA, Rademaker AW, Pauloski BR, et al. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck 2006; 28: 64-73.
21. Hutcheson KA, Barringer DA, Rosenthal DI, May AH, Roberts DB, Lewin JS,. Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 2008; 134: 178-183.
22. Solares CA, Wood B, Rodriguez CP, et al. Does vocal cord fixation preclude nonsurgical management of laryngeal cancer? Laryngoscope 2009; 119: 1130-1134.
23. Hutcheson KA, Lewin JS,. Functional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancers. Curr Oncol Rep 2012; 14: 158-165.
24. Schwartz DL, Hutcheson K, Barringer D, et al. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 1356-1365.
25. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007; 68: 1289-1298.
26. Haddad RI, Rabinowits G, Tisher RB,. The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 30, 2012.
27. Cohen EEW, Karrison T, Kocherginsky M, et al. DeCide: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2012 May 30. J Clin Oncol 2012; 30 (suppl):abstr 5500.
28. Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 4448-4453.